Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Depreciation and Depletion (2020 - 2023)

Insight Molecular Diagnostics (IMDX) has disclosed Depreciation and Depletion for 4 consecutive years, with $404000.0 as the latest value for Q3 2023.

  • Quarterly Depreciation and Depletion rose 3.32% to $404000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Sep 2023, up 32.55% year-over-year, with the annual reading at $1.5 million for FY2022, 81.04% up from the prior year.
  • Depreciation and Depletion hit $404000.0 in Q3 2023 for Insight Molecular Diagnostics, down from $435000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $466000.0 in Q4 2022 to a low of -$216000.0 in Q4 2020.
  • Historically, Depreciation and Depletion has averaged $242733.3 across 4 years, with a median of $262000.0 in 2021.
  • Biggest five-year swings in Depreciation and Depletion: surged 269.57% in 2021 and later grew 3.32% in 2023.
  • Year by year, Depreciation and Depletion stood at -$216000.0 in 2020, then surged by 221.3% to $262000.0 in 2021, then skyrocketed by 77.86% to $466000.0 in 2022, then fell by 13.3% to $404000.0 in 2023.
  • Business Quant data shows Depreciation and Depletion for IMDX at $404000.0 in Q3 2023, $435000.0 in Q2 2023, and $450000.0 in Q1 2023.